Elliott Sigal Overview

  • Investor Type
  • Angel

  • Status
  • Active

  • Professionals
  • 1


  • Investments
  • 3

  • Exits
  • 3


Elliott Sigal General Information


Dr. Elliott Sigal served as Venture Partner and Senior Advisor at New Enterprise Associates. He serves as Board Member at Affinia Therapeutics. He serves as Board Member at Vir (Biotechnology). He serves as a Board Member and Non-Executive Director at Adaptimmune Therapeutics. He served as a Board Member at Spark Therapeutics. He serves as Board Member at Tessera Therapeutics. He joined NEA in 2014. He also served as a Board Member & Member of Nominating, Corporate Governance Committee at Surface Oncology. He is a former Executive Vice President and Director of Bristol-Myers Squibb and served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. He was the principal architect of the successful Biopharma Transformation Strategy of the company. He has been instrumental in increasing R&D productivity, developing the company's strategy in biologics and acquiring external innovation in Bristol's String of Pearls initiative. Under his leadership, fourteen new medicines have come to market including Abilify (Schizophrenia, Bipolar Disorder), Reyataz (HIV/AIDS), Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Atripla (HIV/AIDS), Ixempra (Breast Cancer), Onglyza and Kombiglyze (Diabetes), Nulojix (Transplantation), Eliquis (Anticoagulant), Yervoy (Melanoma), and Forxiga (Diabetes). Among his accomplishments in various therapeutic areas was building BMS research into a leadership position in the promising area of immuno-oncology. In 2012, Mr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. Mr. Sigal currently serves as a senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. Mr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). Prior to medical school, he studied Engineering at Purdue University, where he received a B.S., M.S., and Ph.D. Mr. Sigal serves as a member of the Board of Directors for Mead Johnson Nutrition Company and the Melanoma Research Alliance.

Business Details

Investor Status
Actively Seeking New Investments
Primary Investor Type
Angel (individual)
Corporate Office
  • Princeton, NJ
  • United States

Elliott Sigal Investments (3)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Mersana Therapeutics 02-Mar-2015 Later Stage VC 0000 Biotechnology Generating Revenue/Not Profitable 0000000 00000 00.0
Surface Oncology 21-Nov-2014 00000 00000 000.00 Drug Discovery Generating Revenue/Not Profitable 0000000 00000 00.0
Adaptimmune Therapeutics 19-Sep-2014 00000 00000 00000 Other Commercial Services Generating Revenue/Not Profitable 0000000 00000 00.0

Elliott Sigal Exits (3)

Company Name Exit Date Exit Type Exit Size
Surface Oncology 19-Apr-2018 IPO 00000
Mersana Therapeutics 28-Jun-2017 000 0000
Adaptimmune Therapeutics 06-May-2015 000 00000

Elliott Sigal Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Elliott Sigal Team (1)

Name Title Deals Funds Boards Office
Elliott Sigal Ph.D Angel Investor 0 0 Princeton, NJ

Elliott Sigal FAQs

  • Who is Elliott Sigal?

    Elliott Sigal is an angel Investor who has made 3 investments.

  • What kind of investor is Elliott Sigal?

    Elliott Sigal is an angel investor.

  • What does Elliott Sigal do?

    As an angel investor, Elliott Sigal invests personal money into promising companies, typically in exchange for equity.

  • How many board seats does Elliott Sigal hold?

    Elliott Sigal holds a board seat in Tessera Therapeutics.

  • What has Elliott Sigal invested in?

    Elliott Sigal has made numerous investments in companies like Mersana Therapeutics, Surface Oncology, and Adaptimmune Therapeutics within the Biotechnology, Drug Discovery, and Commercial Services industries.

  • What has Elliott Sigal invested in recently?

    Elliott Sigal's latest investment was on 02-Mar-2015 in Mersana Therapeutics, a company within the Biotechnology industry.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »